Statin therapy is associated with fewer deaths in patients with bacteraemia

Intensive Care Medicine

Volumn 32, Issue 1, 2006, Pages 75-79

  Kruger, Peter ^a   Fitzsimmons, Kenneth ^b   Cook, David ^a   Jones, Mark ^c   Nimmo, Graeme ^a  

^a PRINCESS ALEXANDRA HOSPITAL   (Australia)

^b Ipswich Hospital   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Bacteraemia; HMG CoA reductase inhibitor; Mortality; Statin

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; APACHE; ARTICLE; BACTEREMIA; COHORT ANALYSIS; CONTROLLED STUDY; COURSE EVALUATION; DRUG EFFECT; DRUG EFFICACY; DRUG USE; FEMALE; HOSPITAL BED CAPACITY; HUMAN; INFECTION RATE; MAJOR CLINICAL STUDY; MALE; MORTALITY; RISK REDUCTION; TREATMENT OUTCOME;

ADULT; BACTEREMIA; FEMALE; HOSPITAL MORTALITY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 29844445926     PISSN: 03424642     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00134-005-2859-y     Document Type: Article

References (22)

1. The LIPID Study Group (1998) Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 339:1349-1357
2. Ko DT, Mamdani M, Alter DA (2004) Lipid-lowering therapy with statins in high-risk elderly patients: the treatment-risk paradox. JAMA 291:1864-1870
3. Poldermans D, Bax JJ, Kertai MD, Krenning B, Westerhout CM, Schinkel AF, Thomson IR, Lansberg PJ, Fleisher LA, Klein J, van Urk H, Roelandt JR, Boersma E (2003) Statins are associated with a reduced incidence of perioperative mortality in patients undergoing major noncardiac vascular surgery. Circulation 107:1848-1851
4. Lindenauer PK, Pekow P, Wang K, Gutierrez B, Benjamin EM (2004) Lipid-lowering therapy and in-hospital mortality following major noncardiac surgery. JAMA 291:2092-2099
5. Rosenson RS, Tangney CC (1998) Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA 279:1643-1650
6. Kwak BR, Mach F (2001) Statins inhibit leukocyte recruitment: new evidence for their anti-inflammatory properties. Arterioscler Thromb Vasc Biol 21:1256-1258
7. Almog Y (2003) Statins, inflammation, and sepsis: hypothesis. Chest 124:740-743
8. Liappis AP, Kan VL, Rochester CG, Simon GL (2001) The effect of statins on mortality in patients with bacteremia. Clin Infect Dis 33:1352-1357
9. Blanco-Colio LM, Tunon J, Martin-Ventura JL, Egido J (2003) Anti-inflammatory and immunomodulatory effects of statins. Kidney Int 63:12-23
10. Gordon BR (2004) Poor outcomes associated with low lipid and lipoprotein levels. Crit Care Med 32:878-879
11. Wu A, Hinds CJ, Thiemermann C (2004) High-density lipoproteins in sepsis and septic shock: metabolism, actions, and therapeutic applications. Shock 21:210-221
12. Tai SC, Robb GB, Marsden PA (2004) Endothelial nitric oxide synthase: a new paradigm for gene regulation in the injured blood vessel. Arterioscler Thromb Vasc Biol 24:405-412
13. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR (2001) Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 29:1303-1310
14. Vincent JL, Abraham E, Annane D, Bernard G, Rivers E, Van den Berghe G (2002) Reducing mortality in sepsis: new directions. Crit Care 6(Suppl 3):S1-S18
15. MIMS Online (2004) Prescribing information. Atorvastatin, simvastatin. MIMS Online Australia. Accessed 12 August 2004
16. Drug Reactions Advisory Committee (2004) Risk factors for myopathy and rhabdomyolysis with the statins. Australian Adverse Drug Reactions Bulletin 23:2
17. Knaus WA, Draper EA, Wagner DP, Zimmerman JE (1985) APACHE II: a severity of disease classification system. Crit Care Med 13:818-829
18. Finfer S, Bellomo R, Lipman J, French C, Dobb G, Myburgh J (2004) Adult-population incidence of severe sepsis in Australian and New Zealand intensive care units. Intensive Care Med 30:589-596
19. Kasal J, Jovanovic Z, Clermont G, Weissfeld LA, Kaplan V, Watson RS, Angus DC (2004) Comparison of Cox and Gray's survival models in severe sepsis. Crit Care Med 32:700-707
20. Rice JB, Stoll LL, Li WG, Denning GM, Weydert J, Charipar E, Richenbacher WE, Miller FJ, Jr., Weintraub NL (2003) Low-level endotoxin induces potent inflammatory activation of human blood vessels: inhibition by statins. Arterioscler Thromb Vasc Biol 23:1576-1582
21. Pruefer D, Makowski J, Schnell M, Buerke U, Dahm M, Oelert H, Sibelius U, Grandel U, Grimminger F, Seeger W, Meyer J, Darius H, Buerke M (2002) Simvastatin inhibits inflammatory properties of Staphylococcus aureus alpha-toxin. Circulation 106:2104-2110
22. Gabay C, Kushner I (1999) Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 340:448-454